How to Choose the Right Nonclinical CRO

Selecting a contract research organization for your IND-enabling nonclinical studies is one of the most consequential decisions an early-stage biotech company will make. The right CRO partner accelerates your timeline, produces high-quality data that withstands regulatory scrutiny, and becomes a genuine extension of your team. The wrong one can delay your IND filing by months, produce data that raises more questions than it answers, and consume management bandwidth that should be directed elsewhere. This guide provides a structured approach to CRO selection for biotech companies approaching IND-enabling studies.

When to Start the CRO Selection Process

Most companies underestimate how long CRO selection takes. By the time you factor in initial research, RFP preparation, proposal evaluation, site visits, contract negotiation, and scheduling, the process typically requires 6 to 9 months of lead time before your target study start date.

A Realistic Timeline

Starting CRO selection too late is one of the most common mistakes early-stage companies make. If you are planning to start IND-enabling studies, begin the CRO evaluation process as early as possible, ideally while you are still finalizing your nonclinical strategy.

Defining Your Requirements

Before you can evaluate CROs, you need clarity on what you need. This seems obvious, but many companies begin the selection process without fully defined requirements, which leads to incomplete RFPs and proposals that are difficult to compare.

Key Questions to Answer Before Starting

• What studies do you need? GLP toxicology, pharmacokinetics, biodistribution, genotoxicity, safety pharmacology, immunogenicity assessments? List every study you anticipate needing.
• What species? Rodent (rat, mouse), non-rodent (NHP, dog, rabbit, mini-pig)? Species selection depends on your modality and the relevance of the animal model.
• What modality-specific requirements exist? Gene therapies may require specialized biosafety containment. RNA therapeutics may need specific analytical capabilities. Biologics may require immunogenicity assessments.
• What is your timeline? Work backward from your target IND filing date to determine when studies need to start and finish.
• Do you need GLP compliance? IND-enabling toxicology studies must be conducted under GLP. Earlier studies may not need to be.
• What is your budget range? Having a realistic budget in mind helps focus your search on appropriately sized CROs.

Evaluation Criteria

Scientific Expertise in Your Modality

This is the single most important criterion. A CRO with deep experience in your specific modality, whether that is AAV-based gene therapy, lipid nanoparticle-delivered mRNA, CRISPR-based gene editing, or monoclonal antibodies, will design better studies, anticipate modality-specific challenges, and produce more relevant data.

Questions to ask:

• How many studies have you conducted with this modality in the past 3 years?
• Can you provide case studies or anonymized examples of similar programs?
• Does your study director have direct experience with this type of therapeutic?

Species and Model Access

Not all CROs maintain all species. If your program requires non-human primates, confirm that the CRO has reliable access, adequate housing capacity, and experienced veterinary and technical staff. For specialized models (transgenic animals, disease models, immunodeficient strains), verify availability and lead times.

GLP Compliance History

For pivotal IND-enabling toxicology studies, GLP compliance is not optional. Evaluate the CRO's GLP track record:

• FDA inspection history: Has the CRO been inspected by FDA? What were the outcomes? Minor observations (FDA Form 483s) are common and not necessarily disqualifying. Warning letters are serious red flags. Consent decrees, which are court-ordered agreements that typically restrict or halt operations, are generally disqualifying.
• Quality assurance infrastructure: Does the CRO have a dedicated QA unit? What is their audit process?
• Data integrity practices: How do they manage raw data, electronic records, and audit trails?

Regulatory Track Record

A CRO that has supported successful IND filings understands what regulators expect and how to produce data packages that meet those expectations.

• How many IND-supporting studies has the CRO completed in the past 5 years?
• Have any of their studies been the subject of FDA information requests or clinical holds related to data quality?
• Can they provide references from sponsors who have successfully filed INDs based on their work?

Capacity and Timeline Reliability

CRO capacity fluctuations are a persistent challenge in the industry. A CRO that quotes an attractive timeline but cannot actually deliver on schedule is worse than one that gives you a realistic but longer timeline upfront.

• What is their current capacity utilization?
• How far out are they scheduling new GLP studies?
• What is their track record on delivering studies within the originally quoted timeline?
• Do they have contingency plans for staff turnover or equipment failures?

Pricing Structure

CRO pricing can be opaque. Ensure you understand exactly what is included and what is not.

• Is pricing fixed or based on time and materials?
• What triggers change orders, and how are they handled?
• Are common additions (extra animals, additional time points, extended observation periods) priced in the original proposal or treated as amendments?
• What are the payment terms and milestones?

The RFP Process

A well-structured Request for Proposal (RFP) is essential for getting comparable proposals from multiple CROs.

What to Include in Your RFP

• Company overview: Brief description of your company, therapeutic program, and development stage.
• Study synopsis: Detailed description of each study you are requesting a proposal for, including species, group sizes, dose levels, route of administration, duration, recovery groups, endpoints, and sample collection requirements.
• Timeline requirements: Target start date and any hard deadlines.
• Regulatory context: Specify that studies are intended to support an IND filing and must be conducted under GLP (if applicable).
• Evaluation criteria: Let CROs know how you will evaluate proposals so they can address your priorities.
• Response format: Specify what you want in the proposal (study design, timeline, pricing breakdown, team bios, relevant experience) so proposals are comparable.

How Many CROs to Engage

For most IND-enabling programs, requesting proposals from 3 to 5 CROs provides a good balance between thoroughness and manageability. Fewer than 3 limits your options. More than 5 becomes difficult to evaluate fairly and consumes significant management time.

Evaluating Proposals

Create a structured scoring framework before proposals arrive. Common evaluation dimensions include:

• Scientific approach and study design quality (weighted heavily)
• Modality-specific experience
• Timeline feasibility
• Pricing
• Team qualifications
• GLP compliance and quality infrastructure
• References and track record

Red Flags During CRO Evaluation

Limited Transparency

If a CRO is evasive about their inspection history, pricing structure, or capacity situation, that is a warning sign. Reputable CROs are transparent about their capabilities and limitations.

Unclear or Ambiguous Pricing

Proposals that lack detailed line-item breakdowns, or that include vague language about "additional costs as needed," often lead to significant budget overruns. Insist on clarity before signing.

High Staff Turnover

The study director is your primary point of contact and the person most responsible for study quality. Ask about study director tenure and turnover rates. If the CRO cannot commit to a named study director, or if they have a pattern of study directors leaving mid-study, proceed with caution.

Overpromising on Timelines

If one CRO's proposed timeline is dramatically shorter than the others, ask why. It may reflect genuine efficiency, or it may reflect unrealistic scheduling that will result in delays once the study is underway.

Reluctance to Provide References

Established CROs should be able to provide references from sponsors with similar programs. Reluctance to do so warrants further investigation.

Poor Communication During the Proposal Process

How a CRO communicates during the business development phase is generally the best they will ever communicate. If responsiveness, clarity, or professionalism is lacking during the proposal process, expect it to get worse once the study is underway.

Site Visits and Due Diligence

For IND-enabling studies, conducting a site visit at your finalist CROs is strongly recommended. A site visit gives you direct insight into the CRO's facilities, culture, and operational quality that cannot be assessed from a proposal document.

What to Evaluate During a Site Visit

• Facility condition: Are the animal housing areas, laboratories, and sample storage facilities well-maintained?
• Staff interaction: Do the scientists and technicians seem knowledgeable and engaged? Can you meet the proposed study director?
• Quality systems: Can you tour the QA unit and review their audit processes?
• Data management: How do they handle data capture, review, and archiving?
• Capacity: Does the facility appear to have the capacity they claimed, or does it look stretched?

Contract Negotiation

Once you have selected your preferred CRO, the contracting process begins. Key areas to negotiate:

Scope and Change Orders

• Define exactly what is in scope and what constitutes a change order.
• Establish a change order process that requires written approval before additional work begins.
• Cap the total change order value at a percentage of the original contract to prevent runaway costs.

Timeline Commitments

• Include specific milestones and expected completion dates.
• Define consequences for CRO-caused delays (not delays caused by the sponsor, such as late test article delivery).
• Establish a regular reporting cadence (weekly or biweekly status updates).

Data Ownership and Access

• Ensure you own all raw data and study reports.
• Negotiate real-time or near-real-time access to study data, not just final reports.
• Clarify archiving responsibilities and timelines.

Intellectual Property

• Standard CRO agreements should confirm that all IP generated during the study belongs to the sponsor.
• Review confidentiality provisions carefully, particularly if the CRO works with competitors.

Termination Provisions

• Understand the financial and practical implications of early termination.
• Negotiate reasonable termination fees that reflect actual costs incurred, not penalty-based structures.

Managing the Ongoing CRO Relationship

Selecting the right CRO is only the beginning. Effective ongoing management is what determines whether the partnership succeeds.

Establish Clear Communication Channels

• Designate a single point of contact on each side.
• Set up regular status meetings (weekly during active study phases).
• Define escalation paths for issues that need rapid resolution.

Monitor Proactively

• Review interim data as it becomes available, not just at study completion.
• Attend key study events (dose administrations, necropsies) when feasible.
• Address protocol deviations immediately.

Maintain a Collaborative Relationship

The best CRO relationships are genuine partnerships. Share context about your program and regulatory strategy so the CRO understands why their work matters. When issues arise (and they will), approach them collaboratively rather than adversarially.

Document Everything

Maintain detailed records of all communications, decisions, and protocol amendments. This documentation is valuable for regulatory submissions, audit trails, and institutional memory.

The Role of Preclinical Leadership in CRO Management

For early-stage companies, having experienced preclinical leadership, whether full-time or fractional, overseeing the CRO relationship is essential. A senior preclinical leader brings:

• The scientific judgment to evaluate whether the CRO's study design and execution meet regulatory standards.
• The experience to identify problems early, before they become costly.
• The credibility to push back on CRO recommendations that do not serve the sponsor's interests.
• The relationships within the CRO community to resolve issues efficiently.

Companies that try to manage CRO relationships without experienced preclinical oversight often pay for it in delays, budget overruns, or data quality issues that surface during regulatory review.